Meeting
2012 Genitourinary Cancers Symposium
A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer.
Authors
Stephen V. Liu
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Stephen V. Liu , Andrew V Schally , Tanya B. Dorff , Denice D. Tsao-Wei , Susan G. Groshen , Shigang Xiong , Debra Hawes , David I. Quinn , Yu-Chong Tai , Norman L. Block , Juergen Engel , Jacek K. Pinski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01240629
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 60)
DOI
10.1200/jco.2012.30.5_suppl.60
Abstract #
60
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC).
First Author: Jacek K. Pinski
Poster
2021 Genitourinary Cancers Symposium
Phase I study of entinostat in combination with enzalutamide for treatment of patients with castration-resistant prostate cancer.
First Author: Jianqing Lin
Poster
2017 ASCO Annual Meeting
Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.
First Author: Susan F. Slovin
Poster
2017 Genitourinary Cancers Symposium
A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer.
First Author: Steven Yu